Wilms' tumor has served as an example of Knudson's twohit hypothesis of recessive tumor genes, but the genetics has proven to be surprisingly complex. WT1, a tumor sup pressor gene on llp l3 , is mutated in only a small fraction of Wilms' tumors, and a second chromosomal region, llp l5 , harbors a second Wilms' tumor gene also involved in other cancers. In addition, loss of genomic imprinting, or parental origin-specific gene expression of at least two genes, appears to be an early step in Wilms' tumorigenesis and common cancers. Finally, genes on other chromosomes also play a role. I propose a model of Wilms' tumori genesis in which multiple genetic alterations act within a specific developmental context, accounting for the epi demiological and pathological heterogeneity of Wilms' tumor, as well as the tissue specificity of the tumor types arising from alterations in these genes.
INTRODUCTION
Wilms' tumor (WT) has presented one of the most difficult genetic problems in molecular oncology, but ultimately it may prove to be one of the most informative. WT was one of the three tumors that led Knudson and Strong (1972) to their twohit hypothesis of carcinogenesis. According to this model, patients with bilateral (i.e. multiple independent) tumors have a germline mutation and develop cancer at a younger age than children with unilateral tumors, who must develop two hits in a given somatic cell lineage. Comings (1973) also significantly contributed to these early ideas, in proposing that a recessive cancer gene could act as a dominantly inherited cancer predis position syndrome, if a mutant allele were transmitted through the germline.
The hallmarks of a gene fitting Knudson's model are as follows:
(1) mutations in the causal gene should occur at high frequency in sporadically occurring tumors;
(2) loss of heterozygosity (LOH) in tumors should include the causal gene; (3) re-introduction of the causal gene into tumor cells that are lacking a normal copy should, at least in part, abrogate the tumor phenotype, since the gene is by definition recessive; (4) germline mutations in the gene should underlie familial cases of the tumor.
While another of the original three tumors, retinoblastoma, has met these criteria reasonably well, WT has been far more complicated, as will be discussed here. Neuroblastoma, which is beyond the scope of this article, is even less well understood. Some of the observations regarding the complexity of WT are summarized below, and they show that a simple two-hit model of a single gene is incomplete. I believe that a large part of the answer in understanding them is to view these genetic alter ations in the appropriate developmental context.
WILMS' TUMORS SHOW INFREQUENT MUTATIONS OF THE WT1 GENE ON11P13
The discovery of a homozygous deletion in a Wilms' tumor using anonymous phage clones from the Los Alamos library was one of the first advances in positional cloning of cancer genes. It was accomplished after a heroic effort by the late Bill Lewis, working in a lonely surgery department laboratory at the Hospital for Sick Children in Toronto. Using these mapping reagents, and with considerable additional effort, David Housman's and Gail Bruns' laboratories cloned WT1. This gene was evidently a transcription factor, based upon its five zinc finger motifs resembling a DNA binding protein (Gessler et al., 1990; Call et al., 1990 ). The precise function of WT1 is still unclear, as its precise physiological targets are not completely understood. It shares a DNA binding motif with EGR-1 (Rauscher et al., 1990) . However, it may also serve as a transcriptional inhibitor of IGF2 (Madden et al., 1991) . Fur thermore, additional DNA sequences to which it binds have been identified (Bickmore et al., 1994) . WT1 has been reviewed elsewhere and will not be described in greater detail here (Hastie, 1993; Haber and Housman, 1992) , except for three key aspects of the genetics of WT1:
(a) WT1 fulfills Knudson's two-hit hypothesis of carcino genesis, that a germline mutation in a tumor suppressor gene predisposes individuals to multiple or bilateral tumors at an early age; and sporadic tumors arise from two hits in a somatic cell lineage. Thus, germline mutations in WT1 cause Drash syndrome, or genitourinary malformations plus WT (Pelletier et al., 1991) , and WT1 is the tumor suppressor gene involved in the contiguous deletion syndrome WAGR (Wilms, aniridia, genitourinary malformation, mental retardation) (Huff et al., 1991) . Also, sporadic tumors can show mutations in WT1, with loss of the normal allele (Huff et al., 1991; Brown et al., 1992; Baird et al., 1992) , although mutations in a single allele have also been described (which could act as a dominant negative) (Haber et al., 1990; Kriedberg et al., 1994) .
(b) Despite formal compliance with Knudson's model, the mutation frequency in sporadically occurring tumors is strik ingly low, about 10% (Hastie, 1993; Little et al., 1992) .
(c) About half of Wilms' tumors show loss of expression of WT1, as well as a pseudogene (WIT-1) transcribed in opposite orientation from the same promoter region (Huang et al., 1990) . These tumors are characterized by a relatively early stage of differentiation (Huang et al., 1990) , which has been referred to by Beckwith and colleagues as intralobar nephro genic rest-like (or ILNR-like). ILNRs are residual fetal material often found in tumorous kidneys, or even in normal children (at least 1% of newborn infants), that resemble the immature interior of the developing unit of the kidney, the renal lobe (Beckwith et al., 1990) . Tumors expressing WT1 (and WIT-1) tend to be perilobar nephrogenic rest-like (or PLNR-like) (Huang et al., 1990) . PLNRs are residual fetal material resembling the more mature periphery of the renal lobe (Beckwith et al., 1990 ). An easy histological distinction between ILNRs and PLNRs is the presence in the former of heterologous tissue elements, such as muscle, suggesting a capacity for pleuripotent differentiation of early fetal kidney (Beckwith et al., 1990) . These observations suggest genetic heterogeneity in the pathogenesis of WT.
WILMS' TUMORS INVOLVE INFREQUENT LOH OF WT1 BUT FREQUENT LOSS OF 11p15
Eric Fearon, Bert Vogelstein and I performed an experiment in 1982 that we thought might address Knudson's hypothesis. If two alleles are altered in sporadically occurring tumors, one of them might be altogether lost, which one could detect using polymorphic markers from the same chromosomal arm. The same approach was used by Cavenee and White, without our knowledge, to look at retinoblastoma. We did find loss of het erozygosity (LOH) in WT (Fearon et al., 1984) . As our labo ratory in Michigan eventually discovered, an important differ ence between WT and Rb is that, while chromosome 13 LOH includes the Rb gene (Friend et al., 1984) , LOH on chromo some 11 does not generally involve l i p 13 where the WAGR syndrome was mapped at the time, and where WT1 was later found. Thus, using a panel of markers from throughout lip , we found that the common region of overlap of LOH was 1 lp l5 , not 1 l p l 3 . LOH of llp l5 has also been reported in many common cancers, including bladder (30%) (Fearon et al., 1985) , ovarian (50%) (Zheng et al., 1991) , metastatic breast cancer (50%) (Ali et al., 1987) , and lung (80%) (Weston et al., 1991) . The specific involvement of ll p l5 has been observed by several laboratories (Mannens et al., 1988; Wadey et al., 1990) , although isolated loss of llp l3 does occur rarely (Wadey et al., 1990) . In WT, the frequency of 1 lp l5 LOH is 30%, not very high compared to, for example, 17p loss in colorectal cancer, but 3-fold that of WT1 mutations. Even in the first report of WT1 mutation in sporadic WT, one copy of WT1 had been deleted and the other duplicated. However, the deletion-duplication event had arisen before the mutation, consistent with involvement of a second locus ).
WILMS' TUMORS INVOLVE A TUMOR SUPPRESSOR GENE ON 11p15
The implication of 1 lp l5 LOH is that there is a second tumor suppressor gene on this chromosomal band, which is geneti cally unlinked to llp l3 . In support of this idea, it was shown by Stanbridge's laboratory that, while chromosome 11 sup presses the growth of G401 cells (which are either a WT or rhabdoid tumor cell line), this activity does not require llp l3 but does require 1 lp l5 . They performed this experiment using radiation-treated chromosomes that had deleted either of the two regions (Dowdy et al., 1991) .
We approached the same question directly, by transferring small parts of the chromosome to tumor cells, rather than using the whole chromosome with small parts missing. We term these reagents 'subchromosomal transferable fragments,' or STFs. They were generated by three steps: (1) introduction of a pSV2neo marker into a translocation chromosome 11/X (with 90% of 11 including all of 1 lp, and Xqter with the HPRT gene) monochromosome hybrid in mouse A9 cells; (2) microcell transfer and double selection with HAT and G418 (for chro mosome 11 containing neo); and (3) irradiated microcell transfer into A9 cells, isolating a panel of hybrids with a portion of chromosome 11 (with neo) isolated from the rest of the chromosome. These STFs differ from conventional radiation hybrids in that they can be transferred into virtually any cell, such as a tumor cell, allowing one to score the recipient cell for a phenotype that is selected against, in this case growth inhibition or suppression of tumorigenicity (Koi et al., 1993) .
Using STFs, we could show directly a growth inhibiting effect in vitro of a portion of llp l5 , and we could map this activity to a 4 Mb region between the (3-globin gene cluster and the insulin gene (Koi et al., 1993) . Thus, there is a second tumor suppressor gene on chromosome 11, at band l i p 15.
BECKWITH-WIEDEMANN SYNDROME (BWS), WHICH PREDISPOSES TO WT, MAPS TO 11p15
Another prediction of Knudson's model is that some families with WT should transmit germline mutations of the causal gene. Drash syndrome patients probably cannot do this because of their malformation. However, families with WT unlinked to chromosome 11 have also been described (Grundy et al., 1988; Huff et al., 1988) .
We became interested in BWS when we identified two large kindreds with this disorder, which causes developmental over growth, organomegaly affecting the kidney, liver and tongue, and overproduction of IGF2 and hypoglycemia. Using poly morphic markers from l i p 13 and llp l5 , we mapped this disorder in both families to 1 lpl5.5, close to the insulin gene.
BWS was genetically unlinked to 1 l p l 3 and WT1 (Ping et al., 1989) .
Interestingly, WAGR-associated tumors are associated with ILNRs, representing an early stage of differentiation; and BWS-associated tumors are associated with PLNRs, repre senting a later stage of differentiation (Beckwith et al., 1990) . Furthermore, Breslow and colleagues have observed that children with WT and hemihypertrophy (a characteristic of BWS), develop their tumors at a later age than children with WT and genitourinary malformations (a characteristic of WAGR). Thus, Breslow has suggested genetic heterogeneity in Wilms' tumorigenesis on strictly epidemiological grounds, the original gold standard of the genetics of this disorder (Breslow et al., 1988) . The epidemiology is consistent with the idea of genetic heterogeneity suggested earlier.
BWS INVOLVES GENOMIC IMPRINTING
Finally, WT appears to involve genomic imprinting, a genetic alteration that is generating widespread excitement in cancer biology, and which further complicates the genetics of WT. In an effort to clone the BWS gene, we obtained cells lines from six patients with germline rearrangements involving I Ipl5. By deriving sequence tagged sites (STSs) from throughout this band, we obtained 22 YACs spanning over 6 Mb. With the col laboration of Jan Hoovers and Marcel Mannens, who performed fluorescent in situ hybridization with these YACs, we found that the germline rearrangements are distributed over a surprisingly large region of 5 Mb. Furthermore, all of these balanced rearrangements are derived from the maternally inherited chromosome. On the other hand, several patients with unbalanced duplications of 1 lp l5 have also been reported, and all of these are paternally derived. Thus, the chromosomal translocations in BWS suggest that the maternal allele and paternal allele are different, or imprinted (Little et al., 1991) .
Genomic imprinting is defined as parental origin-specific differential gene expression (Monk, 1988) . BWS would appear to be an imprinted gene, with the paternal allele normally expressed and the maternal allele silent. Two working copies of the gene would cause disease. Thus, in the paternal dupli cations, there are now two working paternal copies. In the balanced rearrangements, the maternal allele has been moved to an autosome where it is transcriptionally activated, according to the model, and there are again two working copies of the gene and thus disease. Junien's laboratory found that 10% of BWS patients have paternal uniparental disomy, or a normal karyotype but with two paternal and no maternal 1 l p l 5 (Henry et al., 1991) . These patients, too, would have two working copies of the gene.
WILMS' TUMOR SHOWS LOSS OF IMPRINTING OF IGF2 AND H19
In order to test the idea directly that genomic imprinting is involved in the pathogenesis of WT, we sought to determine whether two genes imprinted in mouse, and mapping to the BWS candidate region, are imprinted in man and abnormally imprinted in cancer. These are insulin-like growth factor-II (IGF2), an important autocrine and paracrine growth factor in a wide variety of childhood and adult tumors (El-Baldry et al., 1990; Bouffler et al., 1990) ; and H19, an untranslated RNA of obscure function (Brannan et al., 1990) , which inhibits embryo growth in transgenic mice (Brunkow and Tilghman, 1991) .
We used a known transcribed polymorphism in the H I9 gene, and we identified a common polymorphism in an 800 nucleotide CA repeat in the IGF2 gene. This polymorphism is not apparent unless one labels either the 5' or 3' PCR primer and cleaves the product at a nonrepetitive Mvnl site in the middle of the repeat. Using this approach, we found that H19 is transcribed from the maternal allele, and IGF2 from the paternal allele, as has been described in mouse (Rainier et al., 1993) . This was the first direct evidence for an imprinted gene in man.
When we examined WT, we identified a novel type of mutation in man. In 70% of 17 tumors, including WT and a rhabdoid tumor, we found biallelic expression of IGF2. In 30% of tumors, there was biallelic expression of H19 (Rainier et al., 1993) . This compares to a frequency of LOH of 30% and WT1 mutation of 10%. Reeve's laboratory also found biallelic expression of IGF2 in six WTs (Ogawa et al., 1993) . Thus, this alteration is the most frequent yet described in WT. We have coined the term 'loss of imprinting,' or LOI, to describe this alteration. The term LOI has obvious appeal, but it also correctly does not imply mechanism, and is thus not biased toward gene activation or inactivation. It simply means loss of parental origin-specific differential gene expression.
LOI also perfectly fits the imprinting hypothesis of BWS, because in somatic tumors, there are two working copies of an imprinted gene, recapitulating in a Knudsonian way in somatic cells what is seen in the germline in some BWS patients. Also consistent with this model, we have observed LOI in normal tissue of some BWS patients, which has been reported by Weksberg et al. (1993) . However, it remains unproven whether IGF2 is the BWS gene, as the frequency of LOI in normal tissue is relatively low. Nevertheless, there is no question that LOI can precede the development of malignancy.
GENE EXPRESSION IN TUMORS WITH LOI
If abnormal imprinting plays a causal role in tumorigenesis, then a prediction would be that those tumors with LOI should also show abnormal expression of the involved genes. To test this idea, we performed northern blot analysis of IGF2 and H19 on a large number of tumors, comparing them to tumors without LOI or LOH (as both alleles must be present to assess LOI). This is a more accurate control than unaffected kidney, which is embryologically dissimilar, or even fetal kidney, which varies greatly in developmental expression of IGF2 and H19. The prediction was that IGF2 levels should increase in tumors with LOI, and indeed we saw a two-fold increase in these tumors, compared to non-LOI non-LOH tumors. However, the difference was not statistically significant, as the level of expression of IGF2 varied greatly among tumors (Steenman et al., 1994) .
Far more striking was the virtual absence of expression of H19 in those tumors that showed LOI of IGF2. Bear in mind that H19 and IGF2 are at least 100 kb apart on the genome, and thus these data provide strong evidence for their regula tion by a common epigenetic mechanism. Tumors that showed LOI of H19 nevertheless had down-regulated H19 (Steenman et al., 1994) , indicating that LOI of IGF2 is the significant event. Consistent with that idea, all tumors with LOI of H I9 also showed LOI of IGF2. Thus, biallelic expression of H19 (as detected by PCR) may be due to leakage to the paternal chromosome of a factor normally bound to the now unavail able maternal H19 allele, or 'cross-talk' as described in Drosophila. A more prosaic explanation is that tumor cells overexpressing H I9 are selected against, leading to down reg ulation of H19 expression by other transcription factors.
DNA METHYLATION AND GENOMIC IMPRINTING IN WT
Many studies have shown an inverse relationship between DNA méthylation and gene expression. However, it has been difficult to prove a causal link between the two in normal phys iology, although altering DNA méthylation can have dramatic effects on gene expression experimentally.
Nevertheless, there is strong circumstantial evidence linking genomic imprinting to DNA méthylation. In the same issue of the journal in which our observations of LOI were reported, Surani's laboratory showed convincingly that a CpG island at the 5' end of the H19 gene is methylated on the nonexpressed paternal allele and unmethylated on the expressed maternal allele. They accomplished this task by comparing embryos with maternal disomy for chromosome 7 (which harbors IGF2 and H I9) to normal embryos. Maternally disomic embryos were hypomethylated in all tissues, and normal mice were hemimethylated, the exception being sperm DNA, which was hypomethylated (Ferguson-Smith et al., 1993) . Thus, méthyl ation marks the paternal allele, and it occurs after fertilization of the egg.
We used a similar but somewhat reciprocal approach to examine H19 méthylation in man, by comparing DNA of normal individuals to that of BWS patients with paternal uni parental disomy for llp l5 . Four such patients were found among 40 families studied. Like Surani's group, we found hemimethylation of a CpG island in all tissues but sperm, regardless of the state of gene expression. Thus, unlike tradi tional méthylation studies, we are examining parental originspecific tissue-independent DNA méthylation, rather than tissue-specific méthylation. In the UPD patients, both alleles were methylated, although not completely, consistent with the degree of somatic mosaicism for UPD itself (which is postzygotic in BWS) (Steenman et al., 1994) .
These preliminary studies enabled us to determine whether LOI of IGF2 or H19 was associated with any alteration in imprint-specific DNA méthylation. In every case with LOI of IGF2, which involves the maternal allele, the H19 CpG island was methylated, a paternal imprinting pattern. Thus, three changes occurred on the maternal chromosome, all switching it to a paternal epigenotype: activation of IGF2, loss of H19 expression, and méthylation of the H19 CpG island (Steenman et al., 1994) . Whether DNA méthylation is the driving force in these alterations remains unclear, but the data are quite con sistent with those from methyltransferase-deficient mice, in which the H I9 CpG island is hypomethylated, and the paternal as well as maternal alleles of H19 are expressed (and IGF2 is not). In both cases, IGF2 expression is inversely related to méthylation of the H19 CpG island.
A MODEL OF WT: A DEVELOPMENTALLY SPECIFIC CASCADE OF GENETIC ALTERATIONS
I believe that WT, and childhood cancers in particular, should be viewed in a developmentally appropriate context (see Fig.  1 ). Thus, WT1 mutations appear to involve the earliest stages of nephrogenic development. WT1 knockout mice lack normal genitourinary development, and germline mutations are asso ciated with genitourinary malformations (Kriedberg et al., 1994) . According to the model, mutations in WT1 cause an arrest in early nephrogenic development, presenting a persis tent target of nephrogenic precursor cells for subsequent tumorigenic events. Thus, WT1 mutations are quite similar to Rb mutations. Also, like Rb, WT1 is expressed in many meso dermal tissues, yet germline mutations are apparently only largely associated with a specific organ system.
The BWS gene, according to the model, is in large part responsible for expansion of a relatively well differentiated population of cells relatively late in nephrogenic development. It differs in its effects from WT1 in three critical ways. First, its role is later in nephrogenic development. Second, it affects the growth of a wider spectrum of embryonal tissues, including kidney, adrenal, liver, and muscle (Fig. 1) .
Third, the abnormality of the BWS gene in cancer is in a new class of alterations, different from conventional trans forming oncogenes and tumor suppressor genes. Here, the expression of the gene is tightly controlled, and overexpression of the gene (even two-fold from loss of imprinting), leads to overexpansion of cell populations. This overexpansion also presents an increased target for subsequent genetic changes, but it also leads to organomegaly, as seen in BWS, and its effects must occur within a critical developmental window. Thus, BWS patients are at risk for cancer only in early childhood, and they largely outgrow the developmental stigmata of the syndrome over time (Fig. 1) . Furthermore, the BWS gene is involved in expansion of a larger group of tissues, accounting for a larger number of 'embryonal tumors' when overexpressed.
There is yet an additional genetic alteration on l i p in WT, involving a tumor suppressor gene on 1 l p l 5 distinct from the BWS gene. We know that these genes differ because a tumorsuppressing STF from l i p 15 is centromeric to the imprinted region defined by the chromosomal translocation breakpoints in BWS patients, and to IGF2 and H19. However, the tumor suppressor gene is closely linked to the BWS gene and may even be involved in its regulation. Nevertheless, this suppres sor gene, between the (3-globin gene cluster and insulin, appears to be involved in a wide variety of common adult cancers, as well as childhood cancers. It is not necessarily imprinted itself, but loss of the gene would be expected to occur on the maternal chromosome, since paternal losses would by definition also usually delete the functioning copy of IGF2, which would be deleterious to tumor cell growth. The tumor suppressor gene is involved in growth arrest of an even larger number of tissues, with effects both in early develop ment and adult life, accounting for l i p 15 LOH in so many different types of tumors (Fig. 1) . T here are surely other genetic alterations in W ilm s' tum ori genesis. For exam ple we and others have observed 16q loss in 20% o f tum ors, possibly involving the E-cadherin gene (M aw et al., 1992) . O ne o f the m ost interesting questions rem aining to be answ ered is the m echanism o f reduced expression o f WT1 and W IT-1 in ILN R -like tum ors. T hat both 1 lpl3 genes show reduced expression in a concerted w ay suggests that a transcription factor binds to the region betw een these genes and is lacking in som e W ilm s' tum ors. Perhaps this factor is related to fam ilial W T unlinked to chrom osom e 11.
In conclusion, one o f the most im portant lessons o f m olecular oncology is that m ultiple genes are involved in the pathogenesis o f cancer, playing a role at steps o f disease pro gression. The paradigm for this model has been colorectal cancer in adults (Fearon and V ogelstein, 1990) . W hat distin guishes W T, and probably other childhood cancers, as well, is that these genetic alterations involve specific stages o f differ entiation and specific developm ental lineages. These differ ences can in p art explain the organ site specificity for cancer o f these genes, as well as the developm ental w indow for risk o f m alignancy in these patients, both key issues in our efforts to apply genetic know ledge to cancer prevention and treatm ent. 
